Compare HLMN & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLMN | TSHA |
|---|---|---|
| Founded | 1964 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | N/A | 2020 |
| Metric | HLMN | TSHA |
|---|---|---|
| Price | $8.76 | $5.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $12.20 | $10.22 |
| AVG Volume (30 Days) | 978.1K | ★ 3.5M |
| Earning Date | 02-17-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 388.43 | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | ★ $1,536,647,000.00 | $6,310,000.00 |
| Revenue This Year | $7.97 | N/A |
| Revenue Next Year | $7.80 | N/A |
| P/E Ratio | $45.85 | ★ N/A |
| Revenue Growth | ★ 4.47 | N/A |
| 52 Week Low | $6.55 | $1.05 |
| 52 Week High | $10.64 | $6.02 |
| Indicator | HLMN | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 46.01 | 48.63 |
| Support Level | $8.81 | $5.58 |
| Resistance Level | $9.11 | $6.02 |
| Average True Range (ATR) | 0.23 | 0.26 |
| MACD | -0.03 | -0.07 |
| Stochastic Oscillator | 26.63 | 9.88 |
Hillman Solutions Corp is a provider of hardware-related products and related merchandising services to retail markets in North America. The company sells its products to hardware stores, home centers, mass merchants, pet supply stores, and other retail outlets. Its product lines include thousands of small parts such as fasteners and related hardware items; threaded rod and metal shapes; keys and accessories; builder's hardware; personal protective equipment, such as gloves and eye-wear; and identification items, such as tags and letters, numbers, and signs. The segments of the company are Hardware and Protective Solutions, which is the key revenue-generating segment; Robotics and Digital Solutions; and Canada. It has a business presence in the U.S., Canada and Mexico.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.